Abstract 1868: Response biomarkers to IGF1R and mTOR inhibitor combination therapy in ovarian carcinoma
Brian B. Haines(Boston Biomedical Research Institute), Sriram Sathyanarayanan(Boston Biomedical Research Institute), Michael J. Wick(Texas Oncology), Kyriakos P. Papadopoulos(Texas Oncology), Jennifer Tammam(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Nebozhyn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Theresa Zhang(Human Genome Sciences (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jonathan D. Cheng(Princeton University), Leigh Zawel(Howard Hughes Medical Institute)
Cited by 1
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k